Our in-house pipeline is focused on rare Genetic Skeletal Disorders which account for 5% of all birth defects and are an important cause of disability worldwide, yet very few have personalised treatments. In partnership, we are also developing the world’s 1st topical RNA interference therapy in rare ophthalmic disease.
Founded and led by an authority in nanoparticle science for therapeutics, Dr Suzanne Saffie-Siebert Ph.D., our expert team and academic partners are focused on the translation of cutting-edge research into safe, effective, and accessible drugs for currently untreatable diseases.
Our proprietary BIO-COURIER technologies include a next-generation, non-viral, silicon stabilized hybrid Lipid Nanoparticle (sshLNP) to improve the stability, storage, delivery, and immunogenicity of RNA therapeutics.
We are in the midst of a RNA therapeutic revolution, the likes of which have not been seen since the advent of recombinant protein technology almost 50 years ago. SiSaf is at the forefront of stabilizing, storing, and delivering RNA therapeutics, ultimately increasing their access to the global population.
RNA Therapeutics Company SiSaf to Present at Upcoming ConferencesMore
SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical AdvisorMore
SiSaf exercises its option under licencing agreement on gene therapy for rare bone diseaseMore
SiSaf Ltd utilizes Intoolab’s Tzager AI PlatformMore
SiSaf Ltd Announces US$13.2 Million Series B FinancingMore
Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epitheliumMore
SiSaf announces licencing agreement to develop gene therapy for rare bone diseaseMore
SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine ResearchMore
SiSaf Establishes Strategic Partnership with Avellino LabsMore
SiSaf Strengthens it’s Leadership TeamMore
SiSaf Ltd Appoints Former Oxford BioMedica ExecutiveMore
Croda Invests in SiSaf’s Novel Bio-Courier TechnologyMore
UK based biopharmaceutical company SiSaf closes $4.3 million interim funding roundMore
SiSaf’s Chairwoman and Chief Executive Officer, Suzanne Saffie-Siebert featured on BBC Radio 4’s ‘In Business’More
Next-gen silicon nanotechnology drug delivery company SiSaf raises $3.5 million in Series A FundingMore
Silicon Valley Investors Lead Funding Round in SiSafMore
SiSaf Releases latest Clinical Data Showing a 95% Reduction in AcneMore